imipenem

Summary

Summary: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.

Top Publications

  1. pmc Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae
    H Yigit
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 45:1151-61. 2001
  2. ncbi Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia
    Ki Tae Kwon
    Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong, Seoul 135 710, Korea
    J Antimicrob Chemother 59:525-30. 2007
  3. ncbi Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis
    A W Jenney
    Infectious Diseases Unit, Royal Darwin Hospital, Darwin, NT 0810, Australia
    Int J Antimicrob Agents 17:109-13. 2001
  4. pmc Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae
    Laurent Poirel
    Service de Bacteriologie Virologie, Universite Paris XI, Hopital de Bicetre, Assistance Publique Hopitaux de Paris, Faculte de Medecine Paris Sud, 94275 Le Kremlin Bicetre, France
    Antimicrob Agents Chemother 48:15-22. 2004
  5. pmc Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory
    Johann D D Pitout
    Division of Microbiology, Calgary Laboratory Services, 9, 3535 Research Road NW, Calgary, Alberta, Canada T2L 2K8
    J Clin Microbiol 43:3129-35. 2005
  6. pmc High prevalence of metallo-beta-lactamase and 16S rRNA methylase coproduction among imipenem-resistant Pseudomonas aeruginosa isolates in Brazil
    Yohei Doi
    Division of Infectious Diseases, University of Pittsburgh Medical Center, Falk Medical Building Suite 3A, 3601 Fifth Avenue, Pittsburgh PA 15213, USA
    Antimicrob Agents Chemother 51:3388-90. 2007
  7. ncbi Dissemination of imipenem-resistant Acinetobacter baumannii strains carrying the ISAba1 blaOXA-23 genes in a Chinese hospital
    Hua Zhou
    The Key Laboratory of Infectious Disease of Public Health Ministry, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China
    J Med Microbiol 56:1076-80. 2007
  8. ncbi Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin
    Andrea Endimiani
    Laboratorio di Microbiologia, Ospedale di Circolo and Università dell Insubria, Varese, Italy
    Clin Infect Dis 38:243-51. 2004
  9. pmc Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study
    Sang Oh Lee
    Division of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Center for Antimicrobial Resistance and Microbial Genetics, University of Ulsan, Seoul, Korea
    Antimicrob Agents Chemother 48:224-8. 2004
  10. pmc Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes
    Dror Marchaim
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv 64239, Israel
    Antimicrob Agents Chemother 52:1413-8. 2008

Research Grants

  1. Multidrug resistant Acinetobacter baumannii,
    ROBERT BONOMO; Fiscal Year: 2007
  2. Multidrug resistant Acinetobacter baumannii,
    Robert A Bonomo; Fiscal Year: 2010
  3. Multidrug resistant Acinetobacter baumannii,
    ROBERT BONOMO; Fiscal Year: 2009
  4. Antibiotic Hypersusceptibility Mutations in Bacteria
    Alexander Mankin; Fiscal Year: 2005
  5. Antibiotic Hypersusceptibility Mutations in Bacteria
    ALEX NEYFAKH; Fiscal Year: 2004
  6. RESISTANCE TO BETA-LACTAM ANTIBIOTICS
    Shahriar Mobashery; Fiscal Year: 2004
  7. Novel Targets for Treatment of Pseudomonas aeruginosa
    Philip Lister; Fiscal Year: 2007
  8. Epidemiology of emerging pathogens among hospitalizeds patients
    Anthony D Harris; Fiscal Year: 2010
  9. Epidemiology of imipenem-resistant P.aeruginosa
    Anthony Harris; Fiscal Year: 2007
  10. Study design importance in analyzing emerging pathogens
    Anthony Harris; Fiscal Year: 2005

Detail Information

Publications240 found, 100 shown here

  1. pmc Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae
    H Yigit
    Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Antimicrob Agents Chemother 45:1151-61. 2001
    A Klebsiella pneumoniae isolate showing moderate to high-level imipenem and meropenem resistance was investigated. The MICs of both drugs were 16 microg/ml...
  2. ncbi Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia
    Ki Tae Kwon
    Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong, Seoul 135 710, Korea
    J Antimicrob Chemother 59:525-30. 2007
    To investigate the impact of imipenem resistance on the mortality rate among patients with Acinetobacter bacteraemia.
  3. ncbi Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis
    A W Jenney
    Infectious Diseases Unit, Royal Darwin Hospital, Darwin, NT 0810, Australia
    Int J Antimicrob Agents 17:109-13. 2001
    ..Of these 163 (96%) were susceptible to meropenem/imipenem, ceftazidime, trimethoprim-sulphamethoxazole (SMX/TMP) and doxycycline...
  4. pmc Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae
    Laurent Poirel
    Service de Bacteriologie Virologie, Universite Paris XI, Hopital de Bicetre, Assistance Publique Hopitaux de Paris, Faculte de Medecine Paris Sud, 94275 Le Kremlin Bicetre, France
    Antimicrob Agents Chemother 48:15-22. 2004
    ..The beta-lactamase OXA-48 hydrolyzed imipenem at a high level and was remotely related (less than 46% amino acid identity) to the other oxacillinases...
  5. pmc Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory
    Johann D D Pitout
    Division of Microbiology, Calgary Laboratory Services, 9, 3535 Research Road NW, Calgary, Alberta, Canada T2L 2K8
    J Clin Microbiol 43:3129-35. 2005
    ..Using NCCLS disk methodology, inhibition zone diameters were determined in tests with imipenem (IPM) and meropenem (MEM) disks alone and in combination with 930 microg of EDTA...
  6. pmc High prevalence of metallo-beta-lactamase and 16S rRNA methylase coproduction among imipenem-resistant Pseudomonas aeruginosa isolates in Brazil
    Yohei Doi
    Division of Infectious Diseases, University of Pittsburgh Medical Center, Falk Medical Building Suite 3A, 3601 Fifth Avenue, Pittsburgh PA 15213, USA
    Antimicrob Agents Chemother 51:3388-90. 2007
    Rates of metallo-beta-lactamase and 16S rRNA methylase production were investigated in 51 imipenem-resistant Pseudomonas aeruginosa clinical isolates collected from hospitals in São Paulo, Brazil...
  7. ncbi Dissemination of imipenem-resistant Acinetobacter baumannii strains carrying the ISAba1 blaOXA-23 genes in a Chinese hospital
    Hua Zhou
    The Key Laboratory of Infectious Disease of Public Health Ministry, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China
    J Med Microbiol 56:1076-80. 2007
    An outbreak of 95 clinical infections with imipenem-resistant Acinetobacter baumannii in a Chinese hospital was investigated and the carbapenemase-encoding genes and their relationship with ISAba1 of these and a further 16 isolates ..
  8. ncbi Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin
    Andrea Endimiani
    Laboratorio di Microbiologia, Ospedale di Circolo and Università dell Insubria, Varese, Italy
    Clin Infect Dis 38:243-51. 2004
    ..disease" using the McCabe and Jackson classification, were investigated with regard to ciprofloxacin and imipenem response...
  9. pmc Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study
    Sang Oh Lee
    Division of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Center for Antimicrobial Resistance and Microbial Genetics, University of Ulsan, Seoul, Korea
    Antimicrob Agents Chemother 48:224-8. 2004
    Risk factors for the nosocomial occurrence of imipenem-resistant Acinetobacter baumannii (IRAB) were determined. A case-control study design was used for a comparison of two groups of A. baumannii-positive patients with control patients...
  10. pmc Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes
    Dror Marchaim
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv 64239, Israel
    Antimicrob Agents Chemother 52:1413-8. 2008
    The prevalence of isolation of imipenem-resistant Enterobacter (IRE) strains is rising, with potential serious consequences in terms of patients' outcomes and general care...
  11. pmc Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases
    G Bou
    Servicio de Microbiologia, Hospital Ramon y Cajal, 28034 Madrid, Spain
    J Clin Microbiol 38:3299-305. 2000
    ..29 inpatients at Ramón y Cajal Hospital, Madrid, Spain, were determined to be either colonized or infected with imipenem- and meropenem-resistant Acinetobacter baumannii (IMRAB) strains (MICs, 128 to 256 microg/ml)...
  12. ncbi Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections
    Gulseren Baran
    Department of Infectious Diseases and Clinical Microbiology, Ankara Numune Education and Research Hospital, Talatpasa Bulvari, Ankara, Turkey
    Int J Infect Dis 12:16-21. 2008
    To identify the risk factors for nosocomial imipenem-resistant Acinetobacter baumannii (IRAB) infections.
  13. pmc Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii
    María E Pachón-Ibáñez
    Service of Infectious Diseases, Instituto de Biomedicina de Sevilla, Hospitales Universitarios Virgen del Rocio, CSIC, Universidad de Sevilla, Seville, Spain
    Antimicrob Agents Chemother 54:1165-72. 2010
    ..We evaluated the efficacy of rifampin, imipenem, sulbactam, colistin, and their combinations against MDR A...
  14. pmc Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing
    Fred C Tenover
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA
    Emerg Infect Dis 12:1209-13. 2006
    ..In this study, 15 blaKPC-positive Klebsiella pneumoniae that showed discrepant results for imipenem and meropenem from 4 New York City hospitals were characterized by isoelectric focusing; broth microdilution (BMD)..
  15. ncbi Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacter baumannii
    R Srinivasa Rao
    Department of Biotechnology, School of Life Sciences, Pondicherry University, R Venkataraman Nagar, Kalapet, Puducherry, India
    Indian J Med Microbiol 26:333-7. 2008
    ..We also verified the association between biofilm and presence of extended spectrum beta-lactamases, particularly, bla PER-1 ...
  16. doi Clusters of imipenem-resistant Acinetobacter baumannii clones producing different carbapenemases in an intensive care unit
    A Tsakris
    Department of Microbiology, Medical School, University of Athens, Athens, Greece
    Clin Microbiol Infect 14:588-94. 2008
    ..2005-March 2007), 31 intensive care unit (ICU) patients in a Greek hospital were infected or colonised with imipenem-resistant isolates of Acinetobacter baumannii. Twelve patients died, with imipenem-resistant A...
  17. ncbi Imipenem-resistant Achromobacter xylosoxidans carrying blaVIM-2-containing class 1 integron
    Kyeong Seob Shin
    Department of Laboratory Medicine, College of Medicine, Chungbuk National University, Cheongju, 361 711 Republic of Korea
    Diagn Microbiol Infect Dis 53:215-20. 2005
    We characterized seven isolates of imipenem-resistant Achromobacter xylosoxidans that were isolated from patients hospitalized in the intensive care unit at a tertiary hospital in Korea during 2001 to 2003...
  18. pmc A copper-activated two-component system interacts with zinc and imipenem resistance in Pseudomonas aeruginosa
    Olivier Caille
    Department of Microbiology and Molecular Medicine, Centre Medical Universitaire, University of Geneva, 1 rue Michel Servet, 1211 Geneva 4, Switzerland
    J Bacteriol 189:4561-8. 2007
    ..same time caused a decrease in the production of OprD porin, resulting in resistance to the carbapenem antibiotic imipenem. The CzcR regulator was known to repress oprD...
  19. pmc Resistance of Pseudomonas aeruginosa to imipenem induced by eluates from siliconized latex urinary catheters is related to outer membrane protein alterations
    L Martinez-Martinez
    Department of Microbiology, School of Medicine, University of Seville, Spain
    Antimicrob Agents Chemother 43:397-9. 1999
    The activity of imipenem against Pseudomonas aeruginosa HUS-3 decreased by 16 times in the presence of substances eluted from siliconized latex urinary catheters (SLUCs)...
  20. doi Outbreak of imipenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex harboring different carbapenemase gene-associated genetic structures in an intensive care unit
    Yi Tzu Lee
    Department of Medicine, Chutung Veterans Hospital, Chutung, Hsinchu County, Taiwan
    J Microbiol Immunol Infect 45:43-51. 2012
    To investigate the clinical and molecular epidemiology of the imipenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii (IRAcb) complex during an outbreak in an intensive care unit (ICU).
  21. pmc Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel
    Shiri Navon-Venezia
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Israel
    Antimicrob Agents Chemother 50:3098-101. 2006
    ..PCR, sequencing, and Southern blot analysis identified KPC-2 as the imipenem-hydrolyzing enzyme in all four strains, carried on different plasmids with a possible common origin...
  22. pmc In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria
    Elizabeth B Hirsch
    University of Houston College of Pharmacy, Houston, Texas, USA
    Antimicrob Agents Chemother 56:3753-7. 2012
    ..We investigated the combined killing activity of imipenem and MK-7655 against four imipenem-resistant bacterial strains, using a mathematical model previously evaluated in ..
  23. pmc Antimicrobial resistance determinants in imipenem-nonsusceptible Acinetobacter calcoaceticus-baumannii complex isolated in Daejeon, Korea
    Ji Youn Sung
    Department of Biomedical Laboratory Science, Far East University, Eumseong, Korea
    Korean J Lab Med 31:265-70. 2011
    ..In the present study, we investigated the integrons and various genes involved in resistance to carbapenems, aminoglycosides, and fluoroquinolones in 56 imipenem-nonsusceptible Acb complex isolates.
  24. doi Inhibition of a cold-active alkaline phosphatase by imipenem revealed by in silico modeling of metallo-β-lactamase active sites
    Sandeep Chakraborty
    Department of Biological Sciences, Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400 005, India
    FEBS Lett 586:3710-5. 2012
    ..0 after a 30min preincubation) by a specific β-lactam compound (only by imipenem, and not by ertapenem, meropenem, ampicillin or penicillin G)...
  25. pmc Clonal spread of imipenem-resistant Acinetobacter baumannii among different cities of China
    Hua Zhou
    The Key Laboratory of Infectious Disease of Public Health Ministry, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
    J Clin Microbiol 45:4054-7. 2007
    A total of 342 imipenem-resistant Acinetobacter baumannii isolates (IRABs) were collected from 16 Chinese cities. Six predominant clones had spread widely, and four clones were detected in distant hospitals...
  26. pmc OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii
    Paul G Higgins
    Institute for Medical Microbiology, Immunology, and Hygiene, University of Cologne, Cologne, Germany
    Antimicrob Agents Chemother 53:5035-8. 2009
    ..It hydrolyzed penicillins, oxacillin, meropenem, and imipenem but not expanded-spectrum cephalosporins. The bla(OXA-143) gene was located on a ca. 30-kb plasmid...
  27. ncbi Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem
    Jean Luc Mainardi
    INSERM, U872, LRMA Pôle 4, Equipe 12 F 75006 Paris, France
    J Biol Chem 282:30414-22. 2007
    ..Here, we unexpectedly show that imipenem, a beta-lactam of the carbapenem class, totally inhibited Ldt(fm) at a low drug concentration that was sufficient ..
  28. ncbi Differences in phenotypic and genotypic traits against antimicrobial agents between Acinetobacter baumannii and Acinetobacter genomic species 13TU
    Jung Hoon Lee
    Department of Microbiology, Kyungpook National University School of Medicine, Daegu 700 422, Republic of Korea
    J Antimicrob Chemother 59:633-9. 2007
    To investigate the differences in antimicrobial susceptibility and resistance mechanisms against imipenem between Acinetobacter baumannii and Acinetobacter genomic species 13TU.
  29. pmc Increase of ceftazidime- and fluoroquinolone-resistant Klebsiella pneumoniae and imipenem-resistant Acinetobacter spp. in Korea: analysis of KONSAR study data from 2005 and 2007
    Kyungwon Lee
    Department of Laboratory Medicine, Yonsei University College of Medicine, Seodaemun gu, Seoul, Korea
    Yonsei Med J 51:901-11. 2010
    ..We analyzed antimicrobial resistance data generated by Korean Hospitals and by a commercial laboratory in 2005 and 2007...
  30. pmc Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem
    Yuki Katayama
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo, Japan
    Antimicrob Agents Chemother 53:3190-6. 2009
    ..We previously reported that laboratory mutant H14, obtained from VSSA strain Delta IP by exposure to imipenem (IPM), showed overexpression of the vraSR two-component system and a typical hVISA phenotype...
  31. pmc Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain
    Oscar Cirioni
    Clinica delle Malattie Infettive, c o Ospedali Riuniti Ancona, Via Conca 71, 60200 Ancona, AN, Italy
    Antimicrob Agents Chemother 51:2005-10. 2007
    ..has been performed to compare the in vitro activity and the in vivo efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain...
  32. ncbi Impact of antibiotic restriction on broad spectrum antibiotic usage in the ICU of a developing country
    Shahla Siddiqui
    Department of Anaesthesia, Aga Khan University, Karachi
    J Pak Med Assoc 57:484-7. 2007
    ..To reduce rates of nosocomial pneumonia and cost of antibiotic therapy...
  33. pmc Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial
    Samir G Sakka
    Department of Anesthesiology and Intensive Care Medicine, Friedrich Schiller University of Jena, Jena, Germany
    Antimicrob Agents Chemother 51:3304-10. 2007
    ..short-term infusion, results in a superior probability of target attainment as assessed by the fT(>MIC) value of imipenem. In this prospective, randomized, controlled clinical study, patients received either a loading dose of 1 g/1 g ..
  34. pmc Imipenem-EDTA disk method for differentiation of metallo-beta-lactamase-producing clinical isolates of Pseudomonas spp. and Acinetobacter spp
    Dongeun Yong
    Department of Laboratory Medicine, Research Institute of Bacterial Resistance, Yonsei University College of Medicine, 134 Shinchon dong, Seodaemoon ku, Seoul 120 752, Korea
    J Clin Microbiol 40:3798-801. 2002
    ..The method using a disk with imipenem plus 750 micro g of EDTA differentiated all MBL-producing pseudomonads, and the sensitivity and specificity for ..
  35. doi Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia
    Antonio T Freire
    Santa Casa de Misericórdia de Belo Horizonte, Santa Efigenia, Belo Horizonte MG, Brazil
    Diagn Microbiol Infect Dis 68:140-51. 2010
    To compare efficacy and safety of a tigecycline regimen with an imipenem/cilastatin regimen in hospital-acquired pneumonia patients, a phase 3, multicenter, randomized, double-blind, study evaluated 945 patients...
  36. pmc Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2
    Hesna Yigit
    Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA
    Antimicrob Agents Chemother 47:3881-9. 2003
    We investigated a Klebsiella oxytoca isolate demonstrating resistance to imipenem, meropenem, extended-spectrum cephalosporins, and aztreonam. The MICs of both imipenem and meropenem were 32 microg/ml...
  37. pmc Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007
    Stephen P Hawser
    International Health Management Associates Europe Sàrl, 4 Route de la Corniche, 1066 Epalinges, Switzerland
    Antimicrob Agents Chemother 53:3280-4. 2009
    ..ESBL-positive E. coli rates were also relatively high in China (55.0%) and Thailand (50.8%). Ertapenem and imipenem were the most active drugs tested, inhibiting over 90% of all species, including ESBL-positive isolates with the ..
  38. ncbi Comparison of imipenem and ceftazidime as therapy for severe melioidosis
    A J Simpson
    Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Clin Infect Dis 29:381-7. 1999
    ..comparative treatment trial was conducted to compare the therapeutic efficacy of high-dose intravenous imipenem and ceftazidime for acute severe melioidosis...
  39. doi Biofilm formation in Acinetobacter baumannii: associated features and clinical implications
    J Rodríguez-Baño
    Seccion de Enfermedades Infecciosas, Hospital Universitario Virgen Macarena, Sevilla, Spain
    Clin Microbiol Infect 14:276-8. 2008
    ..Fifty-six (63%) isolates formed biofilm. These isolates were less frequently resistant to imipenem or ciprofloxacin than were non-biofilm-forming isolates (25% vs. 47%, p 0.04; and 66% vs. 94%, p 0...
  40. ncbi EDTA susceptibility leading to false detection of metallo-beta-lactamase in Pseudomonas aeruginosa by Etest and an imipenem-EDTA disk method
    Yiu Wai Chu
    Int J Antimicrob Agents 26:340-1. 2005
  41. doi Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes
    Ebbing Lautenbach
    Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6021, USA
    Infect Control Hosp Epidemiol 31:47-53. 2010
    Pseudomonas aeruginosa is one of the most common gram-negative hospital-acquired pathogens. Resistance of this organism to imipenem complicates treatment.
  42. pmc Growth in glucose-based medium and exposure to subinhibitory concentrations of imipenem induce biofilm formation in a multidrug-resistant clinical isolate of Acinetobacter baumannii
    Elisabetta Nucleo
    Department of Biomolecular Sciences and Biotechnology, Universita degli Studi di Milano, Milano, Italy
    BMC Microbiol 9:270. 2009
    ..Acinetobacter baumannii is emerging as an important nosocomial pathogen. Multidrug resistance, as well as ability to withstand environmental stresses, makes eradication of A. baumannii difficult, particularly from hospital settings...
  43. pmc Evaluation of a new Etest for detecting metallo-beta-lactamases in routine clinical testing
    Timothy R Walsh
    University of Bristol, United Kingdom
    J Clin Microbiol 40:2755-9. 2002
    ..Solna, Sweden) gradient formats were developed for detection of metallo-beta-lactamases based on the reduction of imipenem (IP) or ceftazidime (TZ) MICs in the presence of EDTA or 2-mercaptopropionic acid (MPA)...
  44. ncbi Widespread occurrence of aminoglycoside resistance due to ArmA methylase in imipenem-resistant Acinetobacter baumannii isolates in China
    Yun Song Yu
    J Antimicrob Chemother 60:454-5. 2007
  45. pmc Simple microdilution test for detection of metallo-beta-lactamase production in Pseudomonas aeruginosa
    Roberta Migliavacca
    Dipartimento di Scienze Morfologiche, Eidologiche e Cliniche, sez di Microbiologia, Universita di Pavia, 27100 Pavia, Italy
    J Clin Microbiol 40:4388-90. 2002
    A microdilution test measuring imipenem MICs in the presence or absence of a mixture of EDTA plus 1,10-phenanthroline was developed and tested on 190 Pseudomonas aeruginosa isolates, including 18 VIM- and 4 IMP-type metallo-beta-lactamase ..
  46. doi Epidemiology and impact of imipenem resistance in Acinetobacter baumannii
    Ebbing Lautenbach
    Divisions of Infectious Diseases, Department of Medicine, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6021, USA
    Infect Control Hosp Epidemiol 30:1186-92. 2009
    Acinetobacter baumannii is an emerging gram-negative pathogen that can cause healthcare-acquired infections among patients. Treatment is complicated for cases of healthcare-acquired infection with A. baumannii resistant to imipenem.
  47. ncbi Outer-membrane proteins pattern and detection of beta-lactamases in clinical isolates of imipenem-resistant Acinetobacter baumannii from Brazil
    S F Costa
    Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Brazil
    Int J Antimicrob Agents 13:175-82. 2000
    In order to compare imipenem-sensitive and -resistant Acinetobacter baumannii strains isolated from three patients, ribotyping, plasmid, beta-lactamase detection and outer-membrane analysis were performed...
  48. ncbi Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa
    Jing Wang
    Department of Immunology, Tongji Medical College, Wuhan, P R China
    Int J Mol Med 17:309-17. 2006
    ..Therefore in the present study, we examined the effectiveness of phages in the treatment of imipenem-resistant Pseudomonas aeruginosa (IMPR-Pa) infection in an experimental mouse model...
  49. ncbi Clinical study of the effectiveness of imipenem/cilastatin sodium as the antibiotics of first choice in the expectant management of patients with preterm premature rupture of membranes
    Eiji Ryo
    Department of Obstetrics and Gynecology, Japanese Red Cross Medical Center, Tokyo, Japan
    J Infect Chemother 11:32-6. 2005
    We carried out a study to evaluate the effectiveness of imipenem/cilastatin sodium (IPM/CS) in the expectant management of patients with preterm premature rupture of membranes (PPROM)...
  50. doi Emergence of imipenem resistance in clinical Escherichia coli during therapy
    Jesús Oteo
    Antibiotic Laboratory, Bacteriology Service, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Carretera Pozuelo a Majadahonda, 28220 Majadahonda, Madrid, Spain
    Int J Antimicrob Agents 32:534-7. 2008
    ..epidemiology and the mechanisms of resistance of Escherichia coli isolated from two patients infected by imipenem-resistant strains are reported in this study. From one patient, three closely related consecutive isolates of E...
  51. pmc In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid
    Lucio Vera-Cabrera
    Servicio de Dermatologia, Hospital Universitario, Madero y Gonzalitos, Colonia Mitras Centro, Monterrey, NL, Mexico
    Antimicrob Agents Chemother 54:2191-3. 2010
    ..125 and 0.5 microg/ml. The same values for econazole were 2 and 4 microg/ml. The MIC(50) and MIC(90) values of imipenem and meropenem were 64 and >64 microg/ml and 2 and 8 microg/ml, respectively; the addition of clavulanic acid ..
  52. pmc Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem
    Scott A Weisenberg
    Department of Medicine, Weill Medical College of Cornell University, New York, NY 10065, USA
    Diagn Microbiol Infect Dis 64:233-5. 2009
    Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae may appear susceptible to imipenem or meropenem by routine susceptibility testing. We report a series of patients with infections caused by K...
  53. doi Synergistic anti-bacterial and proteomic effects of epigallocatechin gallate on clinical isolates of imipenem-resistant Klebsiella pneumoniae
    Yun Seok Cho
    Department of Biotechnology, Soonchunhyang University, P O Box 97, Asan, Chung Nam 336 600, Republic of Korea
    Phytomedicine 18:941-6. 2011
    b>Imipenem-resistant Klebsiella pneumoniae (IRKP) were used to explore the synergistic anti-bacterial and proteomic effects of imipenem alone or in combination with epigallocatechin gallate (EGCg)...
  54. doi Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp. K04-0144. II. Biological activities
    Atsushi Fukumoto
    Kitasato Institute for Life Sciences and Graduate School of Infection Control Sciences, Kitasato University, 5 9 1 Shirokane, Minato ku, Tokyo, Japan
    J Antibiot (Tokyo) 61:7-10. 2008
    Cyslabdan produced by Streptomyces sp. K04-0144 was found to potentiate imipenem activity against methicillin-resistant Staphylococcus aureus (MRSA). The MIC value of imipenem against MRSA was reduced from 16 to 0...
  55. ncbi A randomized prospective study of cefepime plus metronidazole with imipenem-cilastatin in the treatment of intra-abdominal infections
    J Garbino
    Division of Infectious Diseases, University Hospitals of Geneva, 24 Rue Micheli du Crest, CH 1211 Geneva 14, Switzerland
    Infection 35:161-6. 2007
    ..The aim of this study was to evaluate the efficacy of parenteral cefepime + metronidazole vs imipenem-cilastatin for the treatment of intra-abdominal infections in adult patients.
  56. doi Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem
    Debra A Goff
    College of Pharmacy, The Ohio State University Medical Center, Department of Pharmacy, 410 West 10th Ave, 368 Doan Hall, Columbus, OH 43210, USA
    J Infect 57:123-7. 2008
    To describe any potential effect on in vitro susceptibility to imipenem for aerobic gram-negative bacteria following the addition of ertapenem to the formulary of a large teaching hospital.
  57. doi The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study
    Yehuda Carmeli
    Division of Epidemiology, Tel Aviv Sourasky Medical Center, Tel Aviv 64239, Israel
    Diagn Microbiol Infect Dis 70:367-72. 2011
    Use of the group 2 carbapenems, imipenem and meropenem, may lead to emergence of Pseudomonas aeruginosa resistance. The group 1 carbapenem ertapenem has limited activity against P...
  58. ncbi Structure of the imipenem-hydrolyzing class A beta-lactamase SME-1 from Serratia marcescens
    Wladimir Sougakoff
    Laboratoire de Recherche Moléculaire sur les Antibiotiques LRMA, INSERM EMI0004, Faculté de Médecine Pitié Salpêtrière, Universite Pierre et Marie Curie, 75634 Paris Cedex 13, France
    Acta Crystallogr D Biol Crystallogr 58:267-74. 2002
    ..beta-lactamase SME-1 from Serratia marcescens, a class A enzyme characterized by its significant activity against imipenem, has been determined to 2.13 A resolution...
  59. doi Imipenem heteroresistance induced by imipenem in multidrug-resistant Acinetobacter baumannii: mechanism and clinical implications
    Hao Yuan Lee
    Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Taoyuan, Taiwan
    Int J Antimicrob Agents 37:302-8. 2011
    ..baumannii has been observed worldwide. Here we report the clinical impact and mechanism of imipenem heteroresistance (imipenem minimum inhibitory concentration of 6-32 μg/mL with the presence of resistant cells ..
  60. pmc Metallo-beta-lactamase-producing Pseudomonas spp. in Korea: high prevalence of isolates with VIM-2 type and emergence of isolates with IMP-1 type
    Kyungwon Lee
    Department of Laboratory Medicine, Yonsei University College of Medicine, 250 Seongsan ro, Seodaemun gu, Seoul, Korea
    Yonsei Med J 50:335-9. 2009
    ..Two Korean nationwide studies showed that metallo-beta-lactamases (MBLs)-producing-Pseudomonas spp. are not rare. The aim of this study was to assess the trends of MBL-producing isolates among imipenem-resistant isolates of Pseudomonas spp.
  61. ncbi The in vitro elution characteristics of vancomycin combined with imipenem-cilastatin in acrylic bone-cements: a pharmacokinetic study
    Daniela Cerretani
    Department of Pharmacology G Segre, University of Siena, Siena, Italy
    J Arthroplasty 17:619-26. 2002
    ..aim of this in vitro study was to compare the elution characteristics of vancomycin alone and in combination with imipenem-cilastatin from 3 acrylic bone-cements (CMW1 [DePuy International, Blackpool, UK], Palacos R [Schering-Plough, ..
  62. doi Meropenem monotherapy is as effective as and safer than imipenem to treat brain abscesses
    G Martin-Canal
    Department of Infectious Diseases, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Celestino Villamil s n, 33006 Oviedo, Spain
    Int J Antimicrob Agents 35:301-4. 2010
    ..Fifty-nine adult patients with brain abscesses received either imipenem or meropenem (3-4g/day) or CSC for a mean of 5 weeks, in addition to neurosurgery in most cases...
  63. doi Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem
    Elena Riera
    Servicio de Microbiología and Unidad de Investigación, Hospital Universitari Son Espases, Palma de Mallorca, Spain
    J Antimicrob Chemother 66:2022-7. 2011
    ..175/448) showing non-susceptibility (European Committee on Antimicrobial Susceptibility Testing breakpoints) to imipenem (35%), meropenem (33%) and/or doripenem (33%) recovered in 2008-09 from 16 Spanish hospitals during the ..
  64. pmc Nosocomial outbreak of imipenem-resistant Pseudomonas aeruginosa producing VIM-2 metallo-β-lactamase in a kidney transplantation unit
    S Hammami
    Laboratoire Résistance aux Antimicrobiens, Faculté de Médecine de Tunis Université Elmanar, 15 Rue Djebel Akhdhar La Rabta 1007 Bab Saâdoun Tunis, Tunisie
    Diagn Pathol 6:106. 2011
    Twenty four non replicate imipenem resistant P. aeruginosa were isolated between January and November 2008, in the kidney transplantation unit of Charles Nicolle Hospital of Tunis (Tunisia)...
  65. doi Spread of imipenem-resistant Acinetobacter baumannii of European clone II in Western China
    Chao He
    Department of Laboratory Medicine, West China Hospital, Sichuan University, Sichuan 610041, China
    Int J Antimicrob Agents 38:257-60. 2011
    The aim of this study was to investigate the distribution of resistance genes and the clonal relationship amongst imipenem-resistant Acinetobacter baumannii isolates from ten hospitals in Western China as well as to compare the molecular ..
  66. ncbi Antimicrobial treatment of Capnocytophaga infections
    Anne Jolivet-Gougeon
    Equipe Microbiologie, UPRES EA 1254, CHU Pontchaillou Rennes et Université de Rennes I, 2 Avenue du Professeur Leon Bernard, 35043 Rennes Cedex, France
    Int J Antimicrob Agents 29:367-73. 2007
    ..b>Imipenem/cilastatin, clindamycin or beta-lactamase inhibitor combinations are always effective and their use can be ..
  67. pmc Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial
    Zhangjing Chen
    Huashan Hospital, Fudan University, Shanghai, China
    BMC Infect Dis 10:217. 2010
    ..In the current trial, tigecycline was evaluated for safety and efficacy vs. imipenem/cilastatin in hospitalized Chinese patients with cIAIs.
  68. pmc Spread of integron-associated VIM-type metallo-beta-lactamase genes among imipenem-nonsusceptible Pseudomonas aeruginosa strains in Greek hospitals
    P Giakkoupi
    Department of Hygiene and Epidemiology, Medical School, Athens University, Greece
    J Clin Microbiol 41:822-5. 2003
    Fifty-eight imipenem-nonsusceptible (MIC >or= 8 microg/ml) Pseudomonas aeruginosa strains isolated during May 2001 in 15 Greek hospitals were studied...
  69. ncbi Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains
    M J Rodriguez-Hernandez
    Service of Infectious Diseases, University Hospital Virgen del Rocio, Avenida Manuel Siurot s n, 41013 Sevilla, Spain
    J Antimicrob Chemother 47:479-82. 2001
    Sulbactam and imipenem were compared in an experimental pneumonia model in immunocompetent mice, using a susceptible strain of Acinetobacter baumannii, and in an experimental endocarditis model in rabbits, using an intermediately ..
  70. pmc Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium
    Gaelle Cuzon
    Antimicrob Agents Chemother 52:3463-4. 2008
  71. pmc Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains
    Jung Jr Ye
    Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, Taipei, Taoyuan, Taiwan
    PLoS ONE 5:e9947. 2010
    ..MDRAB) is an important nosocomial pathogen usually susceptible to carbapenems; however, growing number of imipenem resistant MDRAB (IR-MDRAB) poses further clinical challenge...
  72. pmc Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece
    A Tsakris
    Department of Microbiology, Medical School, Aristotle University of Thessaloniki, 54 006 Thessaloniki, Greece
    J Clin Microbiol 38:1290-2. 2000
    Resistance to imipenem and meropenem was observed in 211 (16.5%) isolates of Pseudomonas aeruginosa recovered in a Greek university hospital during 1996 to 1998...
  73. pmc Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula
    Phillip J Bergen
    Facility for Anti Infective Drug Development and Innovation, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
    Antimicrob Agents Chemother 55:5134-42. 2011
    ..investigate in vitro bacterial killing and resistance emergence with colistin alone and in combination with imipenem against multidrug-resistant (MDR) P. aeruginosa...
  74. ncbi Characterization of a carbapenemase-producing clinical isolate of Bacteroides fragilis in Scandinavia: genetic analysis of a unique insertion sequence
    T R Walsh
    Department of Pathology and Microbiology, University of Bristol, Bristol, UK
    Scand J Infect Dis 37:676-9. 2005
    ..K2-28 was shown to possess a functional metallo-beta-lactamase with a reduction in imipenem MIC from 256 to 3 mg/l in the presence of EDTA using the MBL E-test strip...
  75. doi Nosocomial outbreak by imipenem-resistant metallo-beta-lactamase-producing Pseudomonas aeruginosa in an adult intensive care unit in a Brazilian teaching hospital
    Renata Cristina Cezário
    Area Immunology, Parasitology and Microbiology at Universidade Federal de Uberlândia, Uberlândia Minas Gerais, Brazil
    Enferm Infecc Microbiol Clin 27:269-74. 2009
    To describe an outbreak of imipenem-resistant metallo-beta-lactamase-producing Pseudomonas aeruginosa, enzyme type bla, by horizontal transmission in patients admitted to a mixed adult ICU.
  76. ncbi Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients
    Joan R Badia
    UVIR Institut Clínic de Pneumologia i Cirurgia Toràcica, Barcelona, Spain
    J Antimicrob Chemother 54:508-14. 2004
    ..Delivery of antibiotics to the lower respiratory tract could potentially achieve antimicrobial bronchial drug concentrations without toxicity...
  77. doi Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections
    Cristina Suarez
    IDIBELL, Infectious Diseases Service, Hospital Universitari de Bellvitge, University of Barcelona, L Hospitalet de Llobregat, Barcelona, Spain
    J Infect 58:285-90. 2009
    To describe the incidence and clinical characteristics of imipenem-resistant (IR) Pseudomonas aeruginosa bacteraemia.
  78. ncbi In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates
    Thean Yen Tan
    Laboratory Medicine Services, Changi General Hospital, 2 Simei Street 3, Singapore 529889
    J Antimicrob Chemother 60:421-3. 2007
    ..The study investigated the effect of colistin and minocycline when tested singly and in combination against Acinetobacter baumannii...
  79. pmc OXA-60, a chromosomal, inducible, and imipenem-hydrolyzing class D beta-lactamase from Ralstonia pickettii
    Delphine Girlich
    Service de Bacteriologie Virologie, Hopital de Bicetre, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre cedex, France
    Antimicrob Agents Chemother 48:4217-25. 2004
    ..It has a narrow-spectrum hydrolysis profile that includes imipenem. OXA-60-like enzymes were identified in several R. pickettii strains...
  80. pmc Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review
    Marya D Zilberberg
    School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA, USA
    BMC Pulm Med 10:45. 2010
    ..NPs in particular are likely to be caused by Pseudomonas aeruginosa (PA), ~20% of which in observational studies are resistant to imipenem. We sought to identify the burden of PA imipenem resistance in pneumonia.
  81. pmc Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production
    Niels Bagge
    Department of Clinical Microbiology, Rigshospitalet, and Department of Bacteriology, Institute for Medical Microbiology and Immunology, Panum Institute, University of Copenhagen, Denmark
    Antimicrob Agents Chemother 48:1175-87. 2004
    ..used the microarray technology to study the effects of subinhibitory concentrations of a beta-lactam antibiotic, imipenem, on gene expression in biofilm populations...
  82. ncbi Rapid imipenem/cilastatin desensitization for multidrug-resistant Acinetobacter pneumonia
    Sean K Gorman
    CSU Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, British Columbia, Canada
    Ann Pharmacother 37:513-6. 2003
    To report a successful case of rapid imipenem desensitization in a critically ill patient with multidrug-resistant Acinetobacter baumannii ventilator-associated pnemonia (VAP).
  83. doi Prevalence and diversity of carbapenemases among imipenem-nonsusceptible Acinetobacter isolates in Korea: emergence of a novel OXA-182
    Chang Ki Kim
    Korean Institute of Tuberculosis, Seoul 137 900, South Korea
    Diagn Microbiol Infect Dis 68:432-8. 2010
    Increase in multidrug-resistant Acinetobacter poses a serious problem in Korea. In this study, 190 imipenem (IPM)-nonsusceptible (NS) Acinetobacter isolates from 12 Korean hospitals in 2007 were used to determine species, prevalence, and ..
  84. doi First isolation of Burkholderia tropica from a neonatal patient successfully treated with imipenem
    Zakuan Zainy Deris
    Department of Medical Microbiology and Parasitology, School of Medical Sciences, Universiti Sains Malaysia Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia
    Int J Infect Dis 14:e73-4. 2010
    ..Three consecutive blood cultures grew this organism. The organism was cleared from the blood after a course of imipenem and resolution of post-operative ileus...
  85. pmc Structural basis for imipenem inhibition of class C beta-lactamases
    Beth M Beadle
    Department of Molecular Pharmacology and Biological Chemistry, Northwestern University, Chicago, Illinois 60611 3008, USA
    Antimicrob Agents Chemother 46:3978-80. 2002
    To determine how imipenem inhibits the class C beta-lactamase AmpC, the X-ray crystal structure of the acyl-enzyme complex was determined to a resolution of 1.80 A...
  86. pmc The role of patient-to-patient transmission in the acquisition of imipenem-resistant Pseudomonas aeruginosa colonization in the intensive care unit
    J Kristie Johnson
    Department of Pathology, Institute of Genomic Sciences, University of Maryland School of Medicine, 10 South Pine Street, Baltimore, MD 21201, USA
    J Infect Dis 200:900-5. 2009
    b>Imipenem-resistant Pseudomonas aeruginosa (IRPA) is an emerging problem. The causal role of antibiotic selective pressure versus patient-to-patient transmission has not been assessed using a large cohort.
  87. doi The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study
    Ana Lucia L Lima
    Institute of Orthopedics and Traumatology, Hospital das Clinicas, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
    Infect Control Hosp Epidemiol 30:487-90. 2009
    ..Enterobacteriaceae infections in our hospital on the susceptibility of Pseudomonas aeruginosa to imipenem. The use of ertapenem was mandated for treatment of extended-spectrum beta-lactamase-producing Enterobacteriaceae ..
  88. ncbi The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data
    Timothy Babinchak
    Medical Research Group, Wyeth Research, Collegeville, PA 19426, USA
    Clin Infect Dis 41:S354-67. 2005
    ..2 phase 3, double-blind trials designed to evaluate the safety and efficacy of tigecycline, versus that of imipenem-cilastatin, in 1642 adults with complicated intra-abdominal infections...
  89. ncbi Risk factors for ICU-acquired imipenem-resistant Gram-negative bacterial infections
    E Akinci
    Department of Infectious Diseases and Clinical Microbiology, Ankara Numune Education and Research Hospital, Ankara, Turkey
    J Hosp Infect 59:317-23. 2005
    ..This study investigated the risk factors for ICU-acquired imipenem-resistant Gram-negative infections...
  90. ncbi Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures
    Fabrice Michel
    Réanimation Médicale, Hopital Sainte Marguerite, 13274 Marseille Cedex 9, France
    Chest 127:589-97. 2005
    ....
  91. ncbi Risk factors for recovery of imipenem- or ceftazidime-resistant pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil
    Carlos Magno C B Fortaleza
    Universidade Estadual de Campinas, Campinas, Sao Paulo, Brazil
    Infect Control Hosp Epidemiol 27:901-6. 2006
    The prevalence of resistance to imipenem and ceftazidime among Pseudomonas aeruginosa isolates is increasing worldwide.
  92. ncbi Differential effect of imipenem treatment on injury caused by cecal ligation and puncture in wild-type and NK cell-deficient beta(2)-microgloblin knockout mice
    Victor T Enoh
    Department of Anesthesiology, The University of Texas Medical Branch, Galveston, TX 77555 0591, USA
    Am J Physiol Gastrointest Liver Physiol 290:G277-84. 2006
    ..To test this hypothesis, wild-type and beta2MKO/alphaAsGM1 mice were treated with the broad-spectrum antibiotic imipenem immediately after CLP to decrease the impact of systemic infection in our model...
  93. ncbi Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program
    Philip J Turner
    Infection Discovery Department, AstraZeneca, SK10 4TG Macclesfield, Cheshire, UK
    Diagn Microbiol Infect Dis 56:341-4. 2006
    This article examines the activity of meropenem and imipenem against Pseudomonas aeruginosa isolates from the Meropenem Yearly Susceptibility Test Information Collection program between 1997 and 2005...
  94. ncbi Imipenem in patients with immediate hypersensitivity to penicillins
    Antonino Romano
    N Engl J Med 354:2835-7. 2006
  95. ncbi Penicillin-binding proteins of Bacteroides fragilis and their role in the resistance to imipenem of clinical isolates
    Juan Ayala
    Severo Ochoa Molecular Biology Centre, CSIC UAM, 28049 Cantoblanco, Madrid, Spain
    J Med Microbiol 54:1055-64. 2005
    ..The study focused on the role of PBP2Bfr and metallo-beta-lactamase in the mechanism of resistance to imipenem. The mechanism of beta-lactam resistance in B. fragilis was strain dependent...
  96. ncbi Increasing prevalence of imipenem-resistant Pseudomonas aeruginosa and molecular typing of metallo-beta-lactamase producers in a Korean hospital
    In Suk Kim
    Department of Laboratory Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea
    Microb Drug Resist 11:355-9. 2005
    ..and genetic relatedness among Pseudomonas aeruginosa were investigated with a recent high prevalence of imipenem resistance in a Korean hospital. During 2000-2003, a total of 116 non-duplicate imipenem-resistant P...
  97. pmc High prevalence of ceftazidime-resistant Klebsiella pneumoniae and increase of imipenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004
    Kyungwon Lee
    Department of Laboratory Medicine, Yonsei University College of Medicine, 134 Shinchon dong, Seodaemun gu, Seoul 120 752, Korea
    Yonsei Med J 47:634-45. 2006
    ..coli (14%), ceftazidime- and cefoxitin-resistant Klebsiella pneumoniae (34% and 32%, respectively), and imipenem-resistant Acinetobacter spp. and Pseudomonas aeruginosa (17% and 24%, respectively)...
  98. ncbi Impact of carbapenem administration on systemic endotoxemia in patients with severe sepsis and Gram-negative bacteremia
    E J Giamarellos-Bourboulis
    4th Department of Internal Medicine, University of Athens, Medical School, Greece
    J Chemother 18:502-6. 2006
    ..i.d. of imipenem/cilastatin and 10 (group B) 2 g t.i.d. of meropenem...
  99. ncbi bla(OXA-51)-type beta-lactamase genes are ubiquitous and vary within a strain in Acinetobacter baumannii
    Andrea Karina Merkier
    Departamento de Microbiologia, Parasitologia e Inmunologia, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Paraguay 2155, P 12, Capital Federal, Argentina
    Int J Antimicrob Agents 28:110-3. 2006
    ..baumannii pulsed-field gel electrophoresis clones that were susceptible or resistant to imipenem, suggesting a controversial role in imipenem resistance...
  100. pmc Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein
    P A Bradford
    Wyeth Ayerst Research, Pearl River, New York 10965, USA
    Antimicrob Agents Chemother 41:563-9. 1997
    ..Most significantly, three K. pneumoniae strains were also resistant to imipenem (MICs, 8 to 32 micrograms/ml)...
  101. ncbi Imipenem levels are not predictable in the critically ill patient
    Howard Belzberg
    Department of Surgery, Los Angeles County and University of Southern California Medical Center, 90033, USA
    J Trauma 56:111-7. 2004
    Critically ill patients often demonstrate extremely unusual volumes of distribution (Vd) and half-lives (t1/2) of drugs. Imipenem is a widely used antibiotic in critically ill patients.

Research Grants65

  1. Multidrug resistant Acinetobacter baumannii,
    ROBERT BONOMO; Fiscal Year: 2007
    ..derived cephalosporinase (ADC), OXA-23 and OXA-58 like carbapenemases are the major reasons for ceftazidime and imipenem resistance...
  2. Multidrug resistant Acinetobacter baumannii,
    Robert A Bonomo; Fiscal Year: 2010
    ..derived cephalosporinase (ADC), OXA-23 and OXA-58 like carbapenemases are the major reasons for ceftazidime and imipenem resistance...
  3. Multidrug resistant Acinetobacter baumannii,
    ROBERT BONOMO; Fiscal Year: 2009
    ..derived cephalosporinase (ADC), OXA-23 and OXA-58 like carbapenemases are the major reasons for ceftazidime and imipenem resistance...
  4. Antibiotic Hypersusceptibility Mutations in Bacteria
    Alexander Mankin; Fiscal Year: 2005
    ..will identify multiple mutations increasing bacterial susceptibility to beta-lactams (ampicillin, ceftazidime, imipenem), translational inhibitors (erythromycin, linezolid, tetracycline, and chloramphenicol) and fluoroquinolone ..
  5. Antibiotic Hypersusceptibility Mutations in Bacteria
    ALEX NEYFAKH; Fiscal Year: 2004
    ..will identify multiple mutations increasing bacterial susceptibility to beta-lactams (ampicillin, ceftazidime, imipenem), translational inhibitors (erythromycin, linezolid, tetracycline, and chloramphenicol) and fluoroquinolone ..
  6. RESISTANCE TO BETA-LACTAM ANTIBIOTICS
    Shahriar Mobashery; Fiscal Year: 2004
    ..Specific Aim 4 details research in elucidating the mechanistic and structural aspects for turnover of imipenem, a clinically important beta-lactam antibiotic, by the common class A TEM-1 beta-lactamase...
  7. Novel Targets for Treatment of Pseudomonas aeruginosa
    Philip Lister; Fiscal Year: 2007
    ....
  8. Epidemiology of emerging pathogens among hospitalizeds patients
    Anthony D Harris; Fiscal Year: 2010
    ..The reasons for the emergence of A. baumannii are unknown and no interventions have been successful at curbing this emergence. For these reasons, A. baumannii is a significant public health problem. ..
  9. Epidemiology of imipenem-resistant P.aeruginosa
    Anthony Harris; Fiscal Year: 2007
    ..The incidence of antibiotic-resistant bacteria such as imipenem-resistant Pseudomonas aeruginosa is increasing...
  10. Study design importance in analyzing emerging pathogens
    Anthony Harris; Fiscal Year: 2005
    ..The second aim will be done by combining epidemiological relatedness and molecular relatedness through pulse-field gel electrophoresis of ESBL cultures to quantify the importance of patient to patient transmission. ..
  11. New Nosocomial Interventions to Decrease Antimicrobial Resistance Transmission
    Anthony Harris; Fiscal Year: 2007
    ..gown wearing by healthcare workers during all patient contact within the ICU setting will reduce MRSA, VRE, and imipenem-resistant Pseudomonas aeruginosa transmission, and be cost-effective...
  12. QUINOLONE RESISTANCE IN NOSOCOMIAL URINARY INFECTIONS
    Ebbing Lautenbach; Fiscal Year: 2004
    ....
  13. Novel Application of Infection Control Strategies to Limit Transmission of ESBL'S
    Ebbing Lautenbach; Fiscal Year: 2007
    ....
  14. Quinolone resistant E coli in long term care facilities
    Ebbing Lautenbach; Fiscal Year: 2009
    ..abstract_text> ..
  15. Clinical Impact of Quinolone-Resistant E.coli carriage
    Ebbing Lautenbach; Fiscal Year: 2007
    ....
  16. Study of Mechanisms Leading to Multidrug-Resistant K. pneumoniae and A. baumannii
    John Quale; Fiscal Year: 2007
    ..The clinical and economic consequences of nosocomial infections due to multidrug-resistant bacteria are staggering. ..
  17. PLASMID MEDIATED QUINOLONE RESISTANCE
    George Jacoby; Fiscal Year: 2001
    ..Understanding how qnr acts may help to curtail the rise in quinolone resistance and may also provide fundamental insights into aspects of DNA replication. ..
  18. REGULATION OF NEUTROPHIL OXIDATIVE RESPONSES IN TRAUMA
    Joseph Solomkin; Fiscal Year: 2004
    ..Together, these studies will define potential points for therapeutic intervention and provide important insight into regulation of the acute inflammatory response. ..
  19. BIOLOGY OF INFECTIOUS DISEASES TRAINING PROGRAM
    Henry Chambers; Fiscal Year: 2007
    ....
  20. Plasmid-Mediated Quinolone Resistance
    George Jacoby; Fiscal Year: 2007
    ....